First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Julius Strauss; Jean-Laurent Deville; Mario Sznol; Alain Ravaud; Marco Maruzzo; Russell K Pachynski; Theodore S Gourdin; Michele Maio; Luc Dirix; Jeffrey Schlom; Renee N Donahue; Yo-Ting Tsai; XiaoZhe Wang; Yulia Vugmeyster; Frank Beier; Joerg Seebeck; Andreas Schroeder; Sarah Chennoufi; James L Gulley

doi:10.1136/jitc-2022-005813

Citation Tools

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Cite this article as:: Strauss J, Deville J, Sznol M, et al

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Journal for ImmunoTherapy of Cancer 2023;11:e005813. doi: 10.1136/jitc-2022-005813

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password